文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

中国耐多药与广泛耐药结核病患者含贝达喹啉方案的早期结局与安全性:多中心研究

Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study.
PubMed 文献 · Clin Microbiol Infect · 2020-06-15

该多中心研究纳入177例耐多药结核病(MDR-TB)和广泛耐药结核病(XDR-TB)患者,接受24周贝达喹啉联合个体化抗结核背景方案治疗。痰培养转阴率为85.3%,中位转阴时间4周,严重不良事件发生率8.5%,含6例QTc间期延长超过500毫秒。

要点

  • 贝达喹啉联合背景方案治疗MDR-TB和XDR-TB痰培养转阴率高。
  • 低体重指数患者治疗失败风险显著增高(OR 7.356)。
  • 需监测严重不良事件,尤其QTc间期延长。

核心结论

  • 贝达喹啉纳入中国MDR-TB和XDR-TB患者的背景方案中是安全的,且与高痰培养转阴率相关。

研究设计与样本

  • 多中心队列研究,177例MDR-TB和XDR-TB患者接受24周贝达喹啉联合个体化抗结核背景方案治疗。

主要发现

  • 完成24周治疗的177例患者中,151例(85.3%)痰培养转阴,26例结局不良,包括3例(1.7%)死亡和23例(13.0%)无应答。
  • 痰培养转阴中位时间为4周(四分位距2-8周)。
  • MDR-TB患者转阴率为33/39(84.6%,95%CI 73.3-95.9),pre-XDR-TB为47/56(83.9%,95%CI 74.3-93.6),XDR-TB为71/82(86.6%,95%CI 79.2-94.0)。
  • 多因素分析显示低体重指数患者结局不良风险显著增高(比值比7.356;95%CI 2.652-20.401)。
  • 15例(8.5%)发生严重不良事件,包括6例QTc间期延长超过500毫秒。

临床怎么用

  • 对于中国MDR-TB和XDR-TB患者,可考虑使用含贝达喹啉的联合方案,但需密切监测严重不良事件尤其是QTc间期延长,并关注低体重指数患者的不良结局风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Bedaquiline treatment significantly improves multidrug-resistant tuberculosis (MDR-TB) patient treatment outcomes. However, safety and efficacy data are lacking for bedaquiline used with background regimens to treat Chinese TB patients. Here, we describe our initial clinical experience for bedaquiline treatment of a large multicentre cohort of MDR-TB and extensively drug-resistant tuberculosis (XDR-TB) patients in China. METHODS: Patients (177) received 24-week bedaquiline treatment combined with personalized anti-TB drug background regimens. As primary efficacy endpoints, times to initial sputum culture conversion were measured. RESULTS: Of 177 MDR-TB patients completing the 24-week treatment course, sputum culture conversion occurred for 151/177 (85.3%), while 26 had unfavourable outcomes, including 3/177 (1.7%) deaths and 23/177 (13.0%) non-responders at treatment completion. The median time to sputum culture conversion was 4 (interquartile range 2-8) weeks. Conversion rates were 33/39 (84.6%, 95% confidence interval (CI) 73.3-95.9) for MDR-TB patients, 47/56 (83.9%, 95% CI 74.3-93.6) for pre-XDR-TB patients and 71/82 (86.6%, 95% CI 79.2-94.0) for XDR-TB patients. Multivariate analysis demonstrated that patients with low body mass index (odds ratio 7.356; 95% CI 2.652-20.401) were at significantly high risk of unfavourable outcomes, with serious adverse events noted in 15 (8.5%) patients, including six with corrected QT interval (QTc) prolongation times (>500 ms). CONCLUSION: Bedaquiline, when included in background regimens for treatment of MDR-TB and XDR-TB patients in China, was safe and associated with a high rate of culture conversion.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Gao M, Gao J, Xie L, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect. 2020. PMID: 32553880. doi:10.1016/j.cmi.2020.06.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。